Citations

Clear

13603 citation(s) found for "_, _".

Did We Get It All? An Exploratory Study of Goals, Information Needs, and System Requirements for Cancer Surgeons Assessing Breast Tumor Margins
Skurnak, Kaitlin , Zoaktafi, Mojgan, Bourgeois, Gavin , Norasi, Hamid , Wooldridge, Abigail R. , Nadri, Chihab , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | October 15, 2025 | Volume: 69 | Issue: 1 | Pages: 2212-2214

10.1177/10711813251361895 Get It

A positive margin following tumor resection (i.e., surgical removal of a cancerous tumor) indicates that cancer may remain in the body and can require a re-operation. This study is part of a larger project designing a technology to support the intraoperative evaluation of margins. This study explores the goals, decisions, information needs, and system requirements of a surgeon performing breast cancer surgery. We conducted semi-structured interviews with 11 breast surgeons to understand how they currently perform resections and then performed a qualitative thematic analysis. We identified three main goals and 13 subgoals. The three main goals are: treating cancer, meeting patient needs, and meeting institutional needs. Surgeons made multiple decisions to accomplish each sub goal and required multiple information elements to make these decisions. Our results will inform the design of the new technology and a sociotechnical systems-based analysis to ensure the technology fits in surgeon workflow.
Change of guard at Amyloid – a tribute to outgoing Editor in Chief, Professor Per Westermark
Kumar, Shaji

Mayo Clinic

Amyloid | October 15, 2025 | Volume: 32 | Issue: 4 | Pages: 301-302

10.1080/13506129.2025.2574101 | PMID 41089037 Get It

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study
Reed, Damon R. , Janeway, Katherine A. , Hall, David , Crompton, Brian D. , Wang, Wei‐Lien , Zylber, Rebecca, Contreras, Alejandro , Carrero, Giselle, Voss, Stephan D. , Militano, Olga, Pickett, Cheryl A., Fox, Elizabeth , Weigel, Brenda J. , Teachey, David T , Crompton, Brian D , Lazar, Alexander J , Wang, Wei-Lien , Contreras, Alejandro , Voss, Stephan D , Reid, Joel M , Safgren, Stephanie L , Gorlick, Richard , Fox, Elizabeth , Weigel, Brenda J , Reed, Damon R , Minard, Charles G. , Lazar, Alexander J. , Reid, Joel M. , Safgren, Stephanie L. , Görlick, Richard

Mayo Clinic

JCO Oncology Advances | October 14, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-25-00094 | PMID 42131734 Get It

PURPOSE Human epidermal growth factor receptor 2 (HER2), a transmembrane receptor with kinase activity involved in cell signaling through the RAS pathway, is expressed in osteosarcoma (OST). Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate with a HER2-targeting monoclonal antibody, trastuzumab, linked to a topoisomerase I inhibitor. We report results of a phase II study of T-DXd in adolescents and young adults with HER2-positive relapsed, unresectable OST (ClinicalTrials.gov identifier: NCT04616560 ). METHODS Patients age 12-39 years with relapsed, unresectable OST were eligible for centrally evaluated HER2 expression screening by immunohistochemistry. Patients with >10% of OST cells with cytoplasmic or membranous HER2 expression of any intensity were eligible to receive T-DXd at 5.4 mg/kg intravenously once every 3 weeks for up to 2 years. The study used a 9 + 15 Simon's optimal two-stage design with a primary end point of event-free survival at 24 weeks. RESULTS Fifty patients were screened for HER2, and 41 met the inclusion criteria of 10% of OST cells having membranous or cytoplasmic HER2 expression. Nine eligible patients, two younger than 18 years, were enrolled and received T-DXd. With a single patient having more than 24 weeks of stable disease (SD) of the nine planned in the first stage, this study did not meet criteria to progress to stage II. The estimated SD rate at 24 weeks is 11.1%. The median (range) number of cycles of therapy was 2 (2-12). Grade 3 and 4 possibly related adverse events occurred in three of nine patients and included nausea, vomiting, tumor hemorrhage, cytopenias (n = 3), wound infection, and hypertension. CONCLUSION T-DXd did not demonstrate sufficient activity to expand enrollment to the planned second stage in patients with OST. No new safety signals were observed.
Prospects of AI-Powered Bowel Sound Analytics for Diagnosis, Characterization, and Treatment Management of Inflammatory Bowel Disease
Sood, Divyanshi, RIAZ, ZENAB MUHAMMAD, Mikkilineni, Jahnavi, Ravi, Narendra Nath, Chidipothu, Vineeta, Yerrapragada, Gayathri, Poonguzhali, E. , Shariff, Mohammed Naveed , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Asadimanesh, Naghmeh , Karuppiah, Shiva Sankari, Gopalakrishnan, Keerthy, Arunachalam, Shivaram P. , Natarajan, Thangeswaran , Arunachalam, S P , Shariff, Mohammad Naveed

Mayo Clinic

Medical Sciences | October 14, 2025 | Volume: 13 | Issue: 4 | Pages: 230

10.3390/medsci13040230 | PMID 41133513 Get It

Background: This narrative review examines the role of artificial intelligence (AI) in bowel sound analysis for the diagnosis and management of inflammatory bowel disease (IBD). Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, presents a significant clinical burden due to its unpredictable course, variable symptomatology, and reliance on invasive procedures for diagnosis and disease monitoring. Despite advances in imaging and biomarkers, tools such as colonoscopy and fecal calprotectin remain costly, uncomfortable, and impractical for frequent or real-time assessment. Meanwhile, bowel sounds—an overlooked physiologic signal—reflect underlying gastrointestinal motility and inflammation but have historically lacked objective quantification. With recent advances in artificial intelligence (AI) and acoustic signal processing, there is growing interest in leveraging bowel sound analysis as a novel, non-invasive biomarker for detecting IBD, monitoring disease activity, and predicting disease flares. This approach holds the promise of continuous, low-cost, and patient-friendly monitoring, which could transform IBD management. Objectives: This narrative review assesses the clinical utility, methodological rigor, and potential future integration of artificial intelligence (AI)-driven bowel sound analysis in inflammatory bowel disease (IBD), with a focus on its potential as a non-invasive biomarker for disease activity, flare prediction, and differential diagnosis. Methods: This manuscript reviews the potential of AI-powered bowel sound analysis as a non-invasive tool for diagnosing, monitoring, and managing inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. Traditional diagnostic methods, such as colonoscopy and biomarkers, are often invasive, costly, and impractical for real-time monitoring. The manuscript explores bowel sounds, which reflect gastrointestinal motility and inflammation, as an alternative biomarker by utilizing AI techniques like convolutional neural networks (CNNs), transformers, and gradient boosting. We analyze data on acoustic signal acquisition (e.g., smart T-shirts, smartphones), signal processing methodologies (e.g., MFCCs, spectrograms, empirical mode decomposition), and validation metrics (e.g., accuracy, F1 scores, AUC). Studies were assessed for clinical relevance, methodological rigor, and translational potential. Results: Across studies enrolling 16–100 participants, AI models achieved diagnostic accuracies of 88–96%, with AUCs ≥ 0.83 and F1 scores ranging from 0.71 to 0.85 for differentiating IBD from healthy controls and IBS. Transformer-based approaches (e.g., HuBERT, Wav2Vec 2.0) consistently outperformed CNNs and tabular models, yielding F1 scores of 80–85%, while gradient boosting on wearable multi-microphone recordings demonstrated robustness to background noise. Distinct acoustic signatures were identified, including prolonged sound-to-sound intervals in Crohn’s disease (mean 1232 ms vs. 511 ms in IBS) and high-pitched tinkling in stricturing phenotypes. Despite promising performance, current models remain below established biomarkers such as fecal calprotectin (~90% sensitivity for active disease), and generalizability is limited by small, heterogeneous cohorts and the absence of prospective validation. Conclusions: AI-powered bowel sound analysis represents a promising, non-invasive tool for IBD monitoring. However, widespread clinical integration requires standardized data acquisition protocols, large multi-center datasets with clinical correlates, explainable AI frameworks, and ethical data governance. Future directions include wearable-enabled remote monitoring platforms and multi-modal decision support systems integrating bowel sounds with biomarker and symptom data. This manuscript emphasizes the need for large-scale, multi-center studies, the development of explainable AI frameworks, and the integration of these tools within clinical workflows. Future directions include remote monitoring using wearables and multi-modal systems that combine bowel sounds with biomarkers and patient symptoms, aiming to transform IBD care into a more personalized and proactive model.
Response by Johnston et al to Letters Regarding Article, “Risk of Incident Atrial Fibrillation in Women With a History of Hypertensive Disorders of Pregnancy: A Population-Based Retrospective Cohort Study”
Johnston, Amy , Coutinho, Thais , Edwards, Jodi D , Coutinho, Thais D. , Edwards, Jodi D.

Mayo Clinic

Circulation | October 13, 2025 | Volume: 152 | Issue: 15 | Pages: No page available

10.1161/circulationaha.125.075647 | PMID 41082597 Get It

Demographic Trends in Mortality Related to Gastric Cancer in the United States, 1999 to 2022
Dhali, Arkadeep , Faisal, Abdul Rafae , Maity, Rick , Zaman, Asad, Majeed, Mamoona, Hafeez, Ali Shan , Abdullah, Abdullah , Razaq, Laiba, Humayun, Mohammad Abdullah, Qadri, Henna, Dhali, Arkadeep , Maity, Rick , Faizan, Muhammad, Singh, Pramod , Zaman, Asad, Humayun, Mohammad Abdullah

Mayo Clinic

Journal of Clinical Gastroenterology | October 13, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mcg.0000000000002244 | PMID 41081713 Get It

Background: Gastric cancer remains one of the leading causes of death globally and a major health concern. This study aims to analyze gastric cancer-related mortality trends over 2 decades. Methods: The CDC WONDER database was used to analyze and stratify de-identified death certificates from 1999 to 2022 across the United States. Trends in age-adjusted mortality rates (AAMR) were assessed using the Joinpoint Regression Program to determine annual percentage changes. Results: Overall, AAMR decreased from 79.26 in 1999 to 44.81 in 2022. Men and older adults had the highest AAMRs. Non-Hispanic (NH) Black or African Americans had the highest AAMR, while NH Whites had the lowest. Geographically, the Northeast had the highest AAMR, and metropolitan areas had higher AAMRs than nonmetropolitan areas. Conclusion: Gastric carcinoma has a poor prognosis, and although the general trend is decreasing across all sociodemographic areas, further research is required for targeted interventions and health policies for high-risk populations.
Revisiting ‘hot cross bun’ sign: a multicentre MRI study of 97 patients with autopsy-confirmed multiple system atrophy
Sugiyama, Atsuhiko , Mukai, Hiroki , Takao, Masaki , Takeda, Takahiro , Hirano, Shigeki , Yoshida, Mari , Yasui, Keizo, Ando, Takashi , Tamura, Takuya, Middlebrooks, Erik H. , Takahashi, Yuji , Mizutani, Masashi , Mihara, Ban , Komori, Takashi , Hirano, Shigeki , Yoshida, Mari , Ando, Takashi , Sekiya, Hiroaki , Sano, Terunori , Kuwabara, Satoshi , Middlebrooks, Erik H , Riku, Yuichi , Koga, Shunsuke , Yokota, Hajime , Hayashi, Kentarō , Takeda, Takahiro, Iwasaki, Yasushi , Yasui, Keizo, Ito, Yasuhiro , Sekiya, Hiroaki , Dickson, Dennis W. , Sato, Noriko , Komori, Takashi, Kuwabara, Satoshi

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | October 13, 2025 | Volume: No volume available | Issue: No issue available | Pages: jnnp-2025-336869

10.1136/jnnp-2025-336869 | PMID 41083252 Get It

Background The purpose of this study was to clarify the usefulness of the ‘hot cross bun’ sign (HCBS) as a diagnostic imaging marker in a large cohort of patients with multiple system atrophy (MSA) and spinocerebellar ataxia (SCA). Methods This multicentre study included 97 patients with neuropathologically confirmed MSA, and 105 patients with genetically confirmed SCA. Neuroimaging features, including HCBS and middle cerebellar peduncle (MCP) hyperintensities, were assessed. HCBS was graded from 0 to 2: 0, none; 1, only a vertical hyperintense line; and 2, a cruciform hyperintense line. The neuropathological correlates of HCBS were evaluated in 15 patients with MSA with ≤3 months between MRI and autopsy. Results In patients with a disease duration <3 years, grade 1 or 2 HCBS was detected in 100% patients with MSA with predominant cerebellar ataxia (MSA-C) and 39.0% with SCA; whereas grade 2 HCBS was observed in 50% with MSA-C and 2.4% with SCA. Moreover, the coexistence of grade 2 HCBS and MCP hyperintensities exhibited a specificity of 100%. A neuropathological assessment revealed myelin loss, alpha-synuclein aggregates and astrocytic reaction in the MCP, transverse fibres, central zone between longitudinal fasciculi and raphe nucleus, with relative preservation in the longitudinal fasciculi and medial lemniscus in patients with MSA and grade 2 HCBS. Conclusions Grade 1 or 2 HCBS is a highly sensitive finding in patients with MSA-C, and the observation of grade 2 HCBS within 3 years of motor symptom onset has excellent specificity for discriminating MSA-C from SCA, especially when accompanied by MCP hyperintensities.
Treatment of Single Patient With PMM2 ‐Congenital Disorder of Glycosylation With Govorestat ( AT ‐007), an Aldose Reductase Inhibitor
Jalazo, Elizabeth, Weisenfeld, Leigh Anne, Ligezka, Anna N. , Perfetti, Riccardo , Muenzer, Joseph

Mayo Clinic

JIMD Reports | October 13, 2025 | Volume: 66 | Issue: 6 | Pages: No page available

10.1002/jmd2.70043 | PMID 41089670 Get It

ABSTRACT Aldose reductase inhibitors (ARI) have been identified as a potential treatment for phosphomannomutase‐2 congenital disorder of glycosylation (PMM2‐CDG), a serious condition for which no treatments are approved. We treated a single patient for 36 months 30 months of age at enrollment, under a single‐patient investigational new drug expanded access request, with govorestat (AT‐007), a novel, highly selective, once daily, brain penetrant ARI at a starting dose of 1 mg/kg oral suspension, which was escalated to 30 mg/kg. The primary endpoint was safety. Secondary assessments included liver transaminases, factor XI, antithrombin III, and whole blood and urine sorbitol. Clinical outcomes were also assessed, including Nijmegen Pediatric CDG Rating Scale (NPCRS), Bayley Scales of Infant Development, and Vineland Adaptive Behavioral Scale. Govorestat was well tolerated; no adverse effects were noted. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels improved from a pre‐treatment 12‐month average of 205 and 268 U/L to 63 and 68 U/L, respectively, averaged over 36 months of govorestat treatment at 30 mg/kg. Antithrombin III and factor XI fluctuated with illness throughout the study period but overall increased by 60%–100%, approaching the normal range (> 83% activity) at the 5 mg/kg dose. Whole blood sorbitol decreased in a dose‐dependent fashion, normalizing at the 30 mg/kg dose. The NPCRS improved by 9 points (46%) over the course of treatment. In conclusion, our patient tolerated govorestat without safety concerns. Improvements in liver transaminases, clotting factors, and whole blood sorbitol were observed along with improvements in clinical measures. These findings support further study of govorestat as a potential treatment for PMM2‐CDG.
Density and specific gravity of local anesthetic solutions at body temperature
Horlocker, Terese T. , Wedel, Denise J.

Mayo Clinic

Regional Anesthesia: The Journal of Neural Blockade in Obstetrics, Surgery, & Pain Control | October 11, 2025 | Volume: 16 | Issue: Suppl 1 | Pages: 11-11

10.1136/rapm-00115550-199116011-00011 Get It

Is the Incidence of Persistent Paresthesias Increased with Repeated Brachial Plexus Blockade?
Kufner, Ronald P., Horlocker, Terese T. , Besse, Jennifer A., Schroeder, Darrell R.

Mayo Clinic

Regional Anesthesia: The Journal of Neural Blockade in Obstetrics, Surgery, & Pain Control | October 11, 2025 | Volume: 22 | Issue: Suppl 2 | Pages: 40-40

10.1136/rapm-00115550-199722021-00040 Get It